Peter Lynch fit · Growth at a reasonable price (GARP)
Is Summit Therapeutics Inc. Common Stock (SMMT) a Peter Lynch Stock?
Does not fit Lynch's GARP criteria — growth too low or price too high.
26/100
FNo encaja
2/6 criterios cumplidos
Los criterios de Peter Lynch, aplicados a SMMT
PEG ≤ 1.0
clave—
EPS CAGR ≥ 15%
clave0.0%
Revenue CAGR ≥ 10%
150.3%
Net margin > 0
0.0%
Cómo se valora SMMT en otras estrategias
Datos financieros en vivo
Cap. mercado
$12.89B
PER (TTM)
-
ROIC (TTM)
-2.48%
Margen bruto
0.0%
Otros análisis Peter Lynch
Preguntas frecuentes
What is SMMT's Peter Lynch fit score?
SMMT scores 26/100 on our Peter Lynch fit engine — grade F. Does not fit Lynch's GARP criteria — growth too low or price too high.
Does Peter Lynch actually own SMMT?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends SMMT.
How often is this score updated?
SMMT's Peter Lynch fit score is recomputed daily from the latest TTM financials.
Herramienta educativa, no es asesoramiento financiero. Las puntuaciones se calculan a partir de datos financieros públicos contra los criterios publicados de cada estrategia de inversión. No afirmamos que Peter Lynch posea o recomiende SMMT personalmente.